Cart
sales@molnova.com
DGY-06-116
CAS No. ——
DGY-06-116( —— )
Catalog No. M22645 CAS No. ——
DGY-06-116 is an selective and irreversible covalent inhibitor of Src and FGFR1 with IC50 value of 3nM and 8340 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 165 | In Stock |
|
| 5MG | 235 | In Stock |
|
| 10MG | 393 | In Stock |
|
| 25MG | 657 | In Stock |
|
| 50MG | 1007 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDGY-06-116
-
NoteResearch use only, not for human use.
-
Brief DescriptionDGY-06-116 is an selective and irreversible covalent inhibitor of Src and FGFR1 with IC50 value of 3nM and 8340 nM, respectively.
-
DescriptionDGY-06-116 is an selective and irreversible covalent inhibitor of Src and FGFR1 with IC50 value of 3nM and 8340 nM, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetSrc
-
RecptorSrc|FGFR1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight597.11
-
Molecular FormulaC32H33ClN8O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (167.47 mM)
-
SMILESCN1CCN(CC1)c1ccc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)c(Nc3ccccc3NC(=O)C=C)n2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gurbani D , Du G , Henning N J , et al. Structure and Characterization of a Covalent Inhibitor of Src Kinase[J]. Frontiers in Molecular Bioences, 2020, 7:81.
molnova catalog
related products
-
AMG-47a
AMG-47a is a potent inhibitor of Lck and T cell proliferation.?AMG-47a could promote the degradation of the KRAS oncoprotein.?AMG-47a selectively reduced the levels of EGFP-KRASG12V protein but did not affect EGFP protein in cells.
-
PP 3
PP 3 is a Negative control for the Src kinase inhibitor PP 2.
-
KX2-391
KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
